Jia W, et al. (2006) Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res 4, 549-62 16908594

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T308-p - Akt1 (human) ▲

Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene Orthologous residues Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease LY294002 decrease dronabinol LY294002 augment treatment-induced decrease U0126 no change compared to control

S473-p - Akt1 (human) ▲

Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene Orthologous residues Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease LY294002 decrease dronabinol LY294002 augment treatment-induced decrease U0126 no change compared to control

S75-p - BAD (human) ▲

Modsite: EIRsRHssyPAGtED SwissProt Entrez-Gene Orthologous residues BAD (human): S75‑p, BAD (mouse): S112‑p, BAD (rat): S113‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease U0126 decrease dronabinol U0126 augment treatment-induced decrease LY294002 no change compared to control

S99-p - BAD (human) ▲

Modsite: PFrGrsRsAPPNLWA SwissProt Entrez-Gene Orthologous residues BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol no change compared to control U0126 no change compared to control LY294002 decrease dronabinol LY294002 no effect upon treatment-induced decrease

S118-p - BAD (human) ▲

Modsite: GRELRRMsDEFVDsF SwissProt Entrez-Gene Orthologous residues BAD (human): S118‑p, BAD (mouse): S155‑p, BAD (rat): S156‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol no change compared to control U0126 no change compared to control LY294002 no change compared to control

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase phorbol_ester increase U0126 phorbol_ester inhibit treatment-induced increase dronabinol phorbol_ester inhibit treatment-induced increase U0126 dronabinol augment treatment-induced decrease U0126 decrease

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase phorbol_ester increase U0126 phorbol_ester inhibit treatment-induced increase dronabinol phorbol_ester inhibit treatment-induced increase U0126 dronabinol augment treatment-induced decrease U0126 decrease

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase phorbol_ester increase U0126 phorbol_ester inhibit treatment-induced increase dronabinol phorbol_ester inhibit treatment-induced increase U0126 dronabinol augment treatment-induced decrease U0126 decrease

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase phorbol_ester increase U0126 phorbol_ester inhibit treatment-induced increase dronabinol phorbol_ester inhibit treatment-induced increase U0126 dronabinol augment treatment-induced decrease U0126 decrease

T183-p - JNK1 (human) ▲

Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene Orthologous residues JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol no change compared to control PTX no change compared to control

Y185-p - JNK1 (human) ▲

Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene Orthologous residues JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol no change compared to control PTX no change compared to control

S218-p - MEK1 (human) ▲

Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene Orthologous residues MEK1 (human): S218‑p, MEK1 iso2 (human): S192‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase

S222-p - MEK1 (human) ▲

Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene Orthologous residues MEK1 (human): S222‑p, MEK1 iso2 (human): S196‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase

S222-p - MEK2 (human) ▲

Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene Orthologous residues MEK2 (human): S222‑p, MEK2 (mouse): S222‑p, MEK2 (rat): S222‑p, MEK2 (chicken): S220‑p, MEK2 (cow): S222‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase

S226-p - MEK2 (human) ▲

Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene Orthologous residues MEK2 (human): S226‑p, MEK2 (mouse): S226‑p, MEK2 (rat): S226‑p, MEK2 (chicken): S224‑p, MEK2 (cow): S226‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase

T180-p - P38A (human) ▲

Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene Orthologous residues P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol no change compared to control PTX no change compared to control

Y182-p - P38A (human) ▲

Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene Orthologous residues P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol no change compared to control PTX no change compared to control

T359-p - p90RSK (human) ▲

Modsite: DTEFTSRtPKDsPGI SwissProt Entrez-Gene Orthologous residues p90RSK (human): T359‑p, p90RSK iso2 (human): T368‑p, p90RSK (mouse): T348‑p, p90RSK iso3 (mouse): ‑, p90RSK (rat): T359‑p, p90RSK (chicken): T377‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase

S363-p - p90RSK (human) ▲

Modsite: TSRtPKDsPGIPPsA SwissProt Entrez-Gene Orthologous residues p90RSK (human): S363‑p, p90RSK iso2 (human): S372‑p, p90RSK (mouse): S352‑p, p90RSK iso3 (mouse): ‑, p90RSK (rat): S363‑p, p90RSK (chicken): S381‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase

S380-p - p90RSK (human) ▲

Modsite: HQLFRGFsFVAtGLM SwissProt Entrez-Gene Orthologous residues p90RSK (human): S380‑p, p90RSK iso2 (human): S389‑p, p90RSK (mouse): S369‑p, p90RSK iso3 (mouse): ‑, p90RSK (rat): S380‑p, p90RSK (chicken): S398‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol no change compared to control

T573-p - p90RSK (human) ▲

Modsite: AENGLLMtPCytANF SwissProt Entrez-Gene Orthologous residues p90RSK (human): T573‑p, p90RSK iso2 (human): T582‑p, p90RSK (mouse): T562‑p, p90RSK iso3 (mouse): ‑, p90RSK (rat): T573‑p, p90RSK (chicken): T590‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol no change compared to control

S259-p - RAF1 (human) ▲

Modsite: sQRQRststPNVHMV SwissProt Entrez-Gene Orthologous residues RAF1 (human): S259‑p, RAF1 iso2 (human): S259‑p, RAF1 (mouse): S259‑p, RAF1 (rat): S259‑p, RAF1 (chicken): S259‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, T cell lymphoma Relevant cell lines - cell types - tissues:  HUT-78 (T lymphocyte), Jurkat (T lymphocyte), MOLT-4 (T lymphocyte) Cellular systems studied:  cell lines Species studied:  human Comments:  SupT1 cells Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes dronabinol decrease rimonabant dronabinol inhibit treatment-induced decrease SR_144528 dronabinol inhibit treatment-induced decrease Z-VAD-FMK dronabinol no effect upon treatment-induced decrease PTX increase dronabinol PTX inhibit treatment-induced increase